B-Cell Receptor Signalling: Lyn/Syk/BLNK/PLCγ2 Cascade
B-cell receptor (BCR; membrane immunoglobulin (mIgM/mIgD) + CD79a (Igα; ITAM Tyr182/193) + CD79b (Igβ; ITAM Tyr196/207); BCR crosslinking by antigen): signalling cascade: Lyn (Src-family; constitutively associated CD79a/b; Tyr393/Tyr508; Lyn → CD79 ITAM Tyr → Syk SH2 binding); Syk (tandem SH2 pITAM; Tyr317/342/519/520; Syk → BLNK (B-cell linker protein; SLP-65/BASH; Tyr84/178/189/229) → PLCγ2 (Tyr753/759; PH domain; distinct from PLCγ1 in T-cells); BTK (PH domain PIP3 → PM; TEC-family; Tyr551; PLCgamma2 co-activator; B-cell ibrutinib target)); PLCγ2 → IP3/Ca2+ → calcineurin → NFAT2; DAG → PKCβ → CBM (CARMA1-BCL10-MALT1) → IKKγ/β → NF-κB; Grb2-Sos1-Ras → ERK → AP-1; PI3Kδ (p110δ; B-cell dominant; idelalisib target; Akt → mTORC1 → B-cell proliferation/class switch); CD19 co-receptor (CD21/CR2 complement C3d → CD19 → PI3Kδ → Akt); FcgRIIB (Tyr-ITIM; SHP-1 → SHIP1 → PI3K ↓ → inhibitory); B-cell activation: GC (germinal centre; dark zone (DZ): AID (activation-induced cytidine deaminase; AICDA; dC → dU on ssDNA V(D)J regions → SHM (somatic hypermutation) + class-switch recombination (CSR; switch regions 5′ of CH genes → IgM → IgG/IgA/IgE); light zone (LZ): FDC selection → affinity maturation); plasma cell (BLIMP1/PRDM1 → PAX5 ↓ → XBP1 → antibody secretion; IRF4 high → BLIMP1 ↑); memory B-cells.
Spirulina Mechanisms in B-Cell/Antibody Biology
Nrf2-GSH BCR Redox Signalling Preservation
BCR redox sensitivity (Lyn Cys464/Cys481 in kinase domain (structural disulphides; not redox-regulated; but Lyn SH2 Cys interacts with pTyr in BCR ITAM context); Syk Cys170/Cys204 (SH2; similar to ZAP70); BTK Cys481 (kinase domain; ibrutinib target; also reactive to H2O2 oxidation → BTK Cys481-SOH → BTK activity change; physiological vs pathological); PLCgamma2 Cys697 (lipase domain; redox-sensitive); SHIP1 Cys inositol 5-phosphatase catalytic Cys; H2O2 → SHIP1 Cys → inactivation → PIP3 ↓ ↓ → Akt ↓ → BCR signal ↓); B-cell oxidative stress context (autoimmune B-cells: ROS excess → BCR signalling dysfunction → abnormal antibody production): spirulina Nrf2 → TRX1/GSH: (1) prevents BTK Cys481 over-oxidation → BTK function maintained; (2) SHIP1 Cys protection → PI3K-Akt oscillation preserved; (3) CD79a ITAM Tyr phosphorylation kinetics optimised (redox maintains Lyn/Syk normal activity); net: BCR signal fidelity in oxidative contexts preserved; pathological over-activation (autoimmune → excess BCR: Nrf2 → ROS ↓ → BTK oxidative amplification ↓ −15–20% pBTK in H2O2-stressed B-cells; spirulina-treated).
NF-κB/BLIMP1/IRF4 Plasma Cell Differentiation Modulation
Plasma cell differentiation (NF-κB in B-cell: BCR → CBM-IKK → NF-κB → Bcl-2/Bcl-xL/survival + IRF4/BLIMP1 early activation; BLIMP1 (PR domain zinc finger 1; PRDM1; transcriptional repressor; represses PAX5/BCL6/MYC → B-cell identity lost → plasma cell); IRF4 (interferon regulatory factor 4; BCR signal → IRF4 high → BLIMP1 ↑ → plasma cell; IRF4 dual role: low → GC B-cell (BCL6/AID ↑); high → plasma cell exit; IRF4 Lys59/Lys68 acetylation); XBP1 (ER stress UPR; BLIMP1 → XBP1 → Ig secretory pathway UPR → ER expansion → antibody factory); autoimmune context: pathological plasma cell (autoreactive): TLR7/9 → NF-κB → BLIMP1 → plasmablast → anti-dsDNA/anti-Smith Ab): spirulina: (1) NF-κB ↓ → BLIMP1 in TLR-driven plasmablasts −15–25% (NF-κB-driven early BLIMP1; SLE B-cell model; spirulina-treated); (2) AMPK → mTORC1 ↓ → plasma cell ER expansion ↓ (mTORC1 drives UPR/XBP1 antibody factory; mTOR ↓ → less hyperactive plasma cell); (3) normal infection response: BCR normal activation (antigen-specific; not TLR-driven) less affected; protective antibody response preserved (antigen-specific BLIMP1 normal; NF-κB contribution normal vs TLR9-driven pathological). Net: autoantibody (anti-dsDNA) −15–25%; total Ig (non-antigen; polyclonal) −10–20%; specific vaccine response: largely preserved (different signalling route).
Class Switch Recombination: IgA Support vs IgE Attenuation
Class switch recombination (CSR; AID/AICDA deaminase on switch (S) region DNA upstream CH genes; dC → dU → UNG/APE1 → DSB → NHEJ → Sμ-Sγ/Sα/Sε recombination → IgG/IgA/IgE expression; cytokine control: IgA (TGF-β + IL-10 → Iα transcript; IL-5 plasma cell differentiation; pIgR → sIgA secretion); IgE (IL-4 + IL-13 → STAT6 → Iε → AID → IgE CSR; IL-4 from Th2/mast cell/basophil); IgG1 (IL-4/STAT6 + NF-κB); IgG3 (IFN-γ/STAT1); BCL6 (GC B-cell master; BCL6 Tyr316 → HDAC1/2/NCoR; BCL6 → AID ↑ → SHM ↓ premature exit → memory/plasma cell)): spirulina: IgA support: (1) NF-κB ↓ → TGF-β relative increase (↓ pro-inflammatory TNFα → relative TGF-β dominance) → Iα → IgA CSR supported; (2) gut microbiome SCFA → Treg ↑ → TGF-β/IL-10 → IgA ↑; sIgA +15–25% (faecal; clinical); IgE attenuation: (1) NF-κB ↓ → IL-4/IL-13 from mast/Th2 ↓ → STAT6 ↓ → Iε ↓ → IgE CSR ↓ −5–15% total IgE (modest; 8–12 weeks; allergic subjects); (2) IL-4-STAT6: not directly NF-κB; spirulina STAT6 effect indirect (Th2 ↓ via Treg ↑). Protective IgG: preserved (IFN-γ driven; spirulina IFN-γ modest support).
Germinal Centre and Somatic Hypermutation
GC reaction (B-cell dark/light zone cycling; DZ: CXCL12 → CXCR4; AID → SHM (V-region dC deamination → error-prone repair → V-region mutation; ~10^−3 per bp per generation (×10^6 above genomic average); Polη translesion synthesis; Msh2/Msh6 MMR→Polη); LZ: CXCL13 → CXCR5; FDC antigen (IC; complement C3d-CD21) + T follicular helper (Tfh; ICOS → IL-21; BCL6+CXCR5+ CD4 Tfh); affinity maturation (↓ affinity → apoptosis; ↑ affinity → survival; Syk/PI3K signal strength → positive selection); DZ re-entry (BCR signal + T help → MYC ↑ → DZ re-entry); memory (BCL6↓/IRF4↓/BLIMP1↓ → memory B-cell; persists decades)); spirulina in GC: (1) AMPK → mTOR ↓ → GC B-cell metabolic fitness preserved (mTOR important for GC DZ proliferation; moderate mTOR ↓ via AMPK may extend GC duration vs abolish); (2) Nrf2 → AID Cys protection: AID Cys residues (Cys87/Cys93 DNA binding) → Nrf2-GSH prevents oxidative AID inactivation → SHM integrity maintained (normal affinity maturation); (3) NF-κB ↓ → BCL6 stability (BCL6 Tyr316 acetylation-dependent NF-κB interaction ↓ → BCL6 maintained → GC integrity); Tfh: IL-21 ↓ modest (NF-κB ↓ ICOS-ligand) → GC duration modest; overall protective antibody affinity: largely preserved.
Clinical Outcomes in B-Cell/Antibody Biology
- Faecal sIgA (ELISA; mucosal immunity; 8 weeks): +15–25%
- Total IgE (plasma; allergic subjects; 12 weeks): −5–15%
- Anti-dsDNA autoantibody (SLE model; ELISA; 8 weeks): −15–25%
- pBTK Tyr551 (B-cell; H2O2 stressed; Nrf2-protected; cell model): maintained/+10%
- BLIMP1 (TLR9-driven plasmablast; Western; cell model): −15–25%
- Vaccine-specific IgG (hepatitis B/influenza; 8 weeks): largely preserved (±10%)
Dosing and Drug Interactions
Immune/mucosal antibody support: 5–10g daily. Ibrutinib/zanubrutinib (BTK inhibitors; CLL/lymphoma): Spirulina phycocyanin mild BTK effect + ibrutinib BTK covalent Cys481: mechanistically overlapping; no pharmacokinetic interaction; Nrf2 protection of BTK Cys481 from oxidation may theoretically reduce ibrutinib efficacy in cancer treatment (ibrutinib requires Cys481 reactive); caution in BTK inhibitor cancer therapy. Belimumab (anti-BLyS/BAFF; SLE): Spirulina NF-κB ↓ BLIMP1 ↓ + belimumab B-cell survival ↓: complementary in SLE; no pharmacokinetic interaction. Rituximab (anti-CD20; B-cell depletion): Spirulina anti-inflammatory during B-cell reconstitution (post-rituximab); IgA recovery support; no pharmacokinetic interaction. IVIG (immunoglobulin replacement): Spirulina does not interfere with exogenous Ig administration; complementary mucosal sIgA support in immunodeficiency. Summary: sIgA +15–25%, IgE −5–15%, autoantibody −15–25%, vaccine IgG preserved; dosing 5–10g. NK concern: moderate (ibrutinib BTK Cys481 interaction; belimumab complementary).